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Resumo 
 
 
 O glaucoma é uma doença degenerativa ocular que prejudica o nervo ótico do olho, o 
que leva a um aumento da pressão intraocular (IOP) e pode resultar em perda total e 
irreversível de visão. O tratamento disponível até há data baseia-se na administração do 
fármaco brimonidina através de gotas oculares de forma a diminuir a IOP. Porém, a adesão 
dos pacientes ao tratamento de administração de gotas é, em geral, baixa, o que conduz ao 
agravamento da doença. O objetivo desta tese foi desenvolver um filme biocompatível que 
possa servir de revestimento para um dispositivo intraocular, que permita a libertação da 
brimonidina de forma programada, autónoma e in situ. Os filmes foram preparados pela 
técnica camada-sobre-camada e são compostos por monocamadas de brimonidina 
encapsulada em 2-hidroxipropil-ß-ciclodextrina intercaladas por camadas que atrasam a 
libertação do fármaco e que se designam por camadas barreira. Estas últimas são compostas 
por um polímero hidrossolúvel (PBAE) e por bicamadas de óxido de grafeno (GO) compostas 
por grafeno positivo funcionalizado com grupos amina protonados (GONH3+) e por grafeno 
negativo funcionalizado com grupos carboxílicos desprotonados (COO-). Foram preparados 
três tipos de filmes, a diferença entre os dois primeiros filmes foi a alteração da ordem das 
camadas de GO de forma a verificar a sua interação com a camada de brimonidina e o terceiro 
filme apenas contém um tipo de camada barreira compostas por GO, retirando-se o polímero 
hidrossolúvel PBAE, de forma a verificar a sua influencia na cinética de libertação da 
brimonidina. O crescimento dos filmes foi monitorizado por espectroscopia de absorção no 
ultravioleta e visível (UV-Vis) e microscopia de força atómica (AFM) e a cinética de libertação 
do fármaco foi controlada por UV-Vis e por cromatografia líquida de alta eficiência (HPLC). Os 
resultados mostraram que os filmes são estáveis e que a libertação do fármaco pode ser 
controlada pela presença do polímero hidrossolúvel e do óxido de grafeno. Nomeadamente, 
a presença de GO atrasa a libertação de brimonidina por vários dias dependendo do número 
de camadas existentes no filme.  
  
 
 
 
 
 
Palavras-chave: Glaucoma, camada-sobre-camada, libertação controlada de fármacos, 
brimonidina, 2-hidroxipropil-β-ciclodextrina e óxido de grafeno. 
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Abstract 
 
 
Glaucoma is an ocular degenerative disease that damages the eye’s topic nerve, this 
leading to an intraocular pressure (IOP) increase which can result in a total and irreversible 
loss of vision. The available treatment at the moment is based on brimonidine administration 
which allows the decrease of IOP, by administration of ocular drops, in order to decrease IOP. 
However, adherence of patients to the treatment of droplet administration is generally low, 
which leads to the worsening of the disease. The aim of this thesis was to develop a 
biocompatible film that can serve as coating for an intraocular device, allowing the brimonidine 
release to be programmed, autonomous and in situ. The films were prepared by layer-on-layer 
technique and were composed of brimonidine monolayers encapsulated in 2-hydroxypropyl-
β-cyclodextrin interspersed by layers that delay drug release and are referred to as barrier 
layers. These layers are composed of a water soluble polymer (PBAE) and graphene oxide 
(GO) composites composed of graphene positive functionalized with protonated amine groups 
(GONH3+) and negative graphene functionalized with deprotonated carboxylic groups (COO-
). Three types of films were prepared, the difference between the first two films was the change 
in the order of the GO layers in order to verify their interaction with the brimonidine layer and 
the third film only contains a type of barrier layer composed of GO, by removing the water 
soluble polymer PBAE, in order to verify its influence on the brimonidine release kinetics. The 
film growth was monitorized by ultraviolet-visible absorption spectroscopy (UV-Vis) and atomic 
force microscopy (AFM) and the drug release kinetics was followed by UV-Vis absorption 
spectroscopy and high performance liquid chromatography (HPLC). The results have shown 
that the obtained films are stable and the drug release can be controlled by the presence of 
the hydrossoluble polymer and the graphene oxide. Notably, the presence of GO layers delays 
the brimonidine release for several days depending on the number of layers in the film. 
 
 
 
 
 
 
 
 
Keywords: Glaucoma, layer-by-layer, controlled drug delivery, brimonidine, 2-hydroxypropyl-
β-cyclodextrin and graphene oxide.  
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1.Introduction 
 
1.1 Glaucoma and drug delivery systems for ocular devices 
 
1.1.1 Glaucoma 
 
According to the World Health Organization, glaucoma is one of the diseases that 
causes total blindness. It is estimated that the number of persons affected by glaucoma 
is about 4.5 million and that globally this disease is the second leading cause of blindness 
(6). Also, it is predicted that by 2020, close to 4 millions of Americans will have glaucoma 
from which ca. 50% will be undiagnosed and approximately 120,000 individuals will 
develop blindness (7) (8). Glaucoma is characterized by an optic neuropathy that leads 
to progressive vision loss and in more extreme cases causes blindness. It is a chronic 
and degenerative neuropathy that can be distinguished by the characteristic appearance 
of the optic nerve (9) (10) (11). It is characterized by elevated intraocular pressure; 
development of optic nerve atrophy, and loss of the peripheral field of vision, culminating 
in the so-called “impairing central vision” (Figure 1) (12). The risk factors are mostly age, 
gender, race and genetics, but the major cause is elevated intraocular pressure (IOP) 
(10)(13). 
 
  
The IOP can be determined by the rate of the aqueous outflow and the episcleral 
venous pressure (14). The available treatment so far is mostly pharmacologically and 
surgically that allows for stabilizing the IOP with eye drops composed of alpha2-
Figure 1 - Progression of vision loss of a person with open angle glaucoma. 
(from http://www.floridaeyespecialistinstitute.com/services/glaucoma/ in 2016.11.08) 
 
 
3 
adrenergic agonists (i.e. Brimonidine). The surgery contributes to create a new opening 
which helps the fluid to leave the eye, and consequently lowers the IOP. However, the 
patient needs to administrate eye drops on a daily basis, this representing the major 
problem on the present treatment of glaucoma, since a significant lack of patients´ 
adherence to the daily topical treatment has been verified (patients’ do not renew their 
prescriptions resulting in regularly missing doses) (7)(13). 
A schematic representation of the effect of IOP in the human eye, can be seen in 
figure 2. The eye affected by glaucoma shows aqueous humour that is not correctly 
drained, leading to an increase of pressure.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 - Schematic representation of a normal eye comparing with an eye with 
glaucoma. Adapted from (60). 
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Figure 3 represents a diagram showing the structures that are affected by high 
IOP and the effects of the glaucoma at a high developing state (vision loss). 
 
 
 
Thus, considering the poor IOP control provided by the current treatments, it is 
therefore imperative to develop a method of drug delivery which does not depend on the 
patient compliance.  
  
1.1.2 Drug Delivery 
 
Drug delivery (DD) refers to a formulation or a device that enables the insertion 
and transport of a therapeutic substance in the body. Currently great efforts have been 
dedicated to the development of targeted and controlled DD, by accurately controlling 
the rate, time, and place of release of drugs in the body. An ideal DD system should 
present  the following  features (15): 
• It should increase the bioavailability of the drug; 
• It should provide for controlled DD; 
Figure 3 - Most common factors of glaucoma triggered by elevated intraocular 
pressure and its structural and functional consequences (12). 
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• It should transport the drug intact to the site of action while avoiding the non-
diseased host tissues;  
• The product should be stable and the delivery should be maintained under 
various physiological variables; 
• Its administration to the patients should be easy; 
• It should be safe and reliable; 
• It should be cost-effective. 
A DD system can be characterized by the following properties:  
• Physical state - the dosage forms can be administrated in gaseous form (e.g. 
anaesthetic), liquid (e.g. solutions, emulsions, suspensions), semi-solid (e.g. 
cream, ointments, gel and pasts) and solid dosage (e.g. powders, granules, 
tablets and capsules). Some cases have more than one type of physical state. In 
this thesis, the developed DD system has a solid form.  
• Route of administration - drugs can be administrated directly into the body, 
through injection or infusion. Depending on the site of administration, it is possible 
to differentiate between intravenous, intramuscular, subcutaneous, intradermal 
and intraperitoneal. In this thesis, the developed DD system to release the drug 
is in situ. 
• Mechanism of drug release - the drug release process can be classified as an 
immediate release, where the drug is released immediately after administration, 
and a modified release, that occurs after administration or to a specific target in 
the body. This modified release can be classified as delayed release, where the 
drug is released only at some point after the initial administration or it could be 
an extended release, i.e. the release is prolonged to reduce the dosing frequency. 
In this thesis, the developed DD systems function accordingly to a modified 
release and  the two different kinds were developed: delayed and extended 
release (16). 
 
1.1.3 Time-controlled drug delivery 
  
The control of time and dosage of the therapeutic drugs is crucial to improve 
patient care but a very precise control of the DD mechanism is required to allow for 
enlarging the period of release from a few hours to long periods, as months, which are 
generally convenient. 
 
6 
A time-controlled DD system should provide a sequential release of the drug 
improving its delivery and its availability at the target organ/tissue. These systems can 
be prepared as multilayer films which can coat devices placed either inside or on the 
surface of the body (17). 
A recent work developed by Paula T. Hammond et al. (17) demonstrated a 
controlled DD system, consisting of a multilayer film which included graphene oxide as 
a barrier layer to delay the drug release. In such study, the number of graphene oxide 
(GO) layers was found to be proportional to the time delay of the drug and the extend 
the drug release from 30 to 90 days by varying the number of bilayers of functionalized 
GO (17). Such barrier layers to delay the drugs release act as grouped films in order to 
regulate the drug release and also regulate interlayer diffusion. By alternating layers of 
polyelectrolytes exhibiting linear growth, within the film, such as of poly(allylamine 
hydrochloride) (PAH), poly(acrylic acid) (PAA), poly(styrene sulfonate) (PSS) and 
Poly(ß-amino esters)	 (PBAE), it is also possible to accomplish the release of multiple 
drug types in an ordered and temporally controlled manner (17) (18). 
 
1.1.4 Drug delivery layer-by-layer films for biomedical applications 
 
The layer-by-layer (LbL) assembly was introduced for the first time by Decher, in 
1992 (19), as an assembly technique based on complementary chemical interactions. 
This technique involves the alternating adsorption of different charged molecular species 
from buffered aqueous media to build a film. It provides an alternative approach to 
traditional polymer-based delivery systems, since the polymer delivery matrix is built one 
layer at a time and the drug of choice is inserted in alternated layers (17). LbL assembly 
is a cyclical process in which a charged material is adsorbed onto a substrate, and after 
washing, an oppositely charged material is adsorbed on top of the first layer. Figure 4 
depicts a schematic representation of the process (20). 
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The LbL assembly technique is versatile, allowing the incorporation of a broad 
range of functional polymers, biomacromolecules and other charged species (17) (19). 
Besides simplicity, the LbL method offers several advantages, such as: allows for 
a precise control of the coating properties; it is environmentally friendly; it is low-cost; it’s 
versatility for coating a wide range of surfaces; provides homogeneous films with 
controlled thickness and allows the incorporation and controlled release of 
biomolecles/drugs (21) (20). The process of LbL allows for depositing not only water-
soluble linear charged polymers, but also viruses, proteins, dyes, metal oxides, 
amphiphilic molecules, etc (21). Remarkably, the LbL technique has been already used 
for functionalizing scaffolds and medical devices for different applications. In the medical 
field, this method has been mostly used to prepare DD vehicles, more specifically 
multilayer coatings fabricated on the top of a nanoparticle core. The core is then removed 
in order to obtain an empty shell that can be loaded and functionalized with different 
biomolecules or drugs (21). The interdiffusion and mixing of polyionic species during 
assembly can limit the ability to control the film architecture for many biomedical 
applications; thus, such multilayer films release biologic drugs with little or no control of 
drug sequence (17).  
The LbL method used in this thesis to prepare the DD films allowed a sequential 
adsorption of several layers immersing a charged substrate in a different polymer 
solution. After each immersion in a polymer solution, the sample should be washed, in 
order to remove the physically adsorbed particles, ensuring that the remaining layers are 
homogeneous (20). This procedure can be repeated as many times as necessary until 
the desired number of layers is achieved. 
 
 Figure 4 - Schematic representation of the LbL method. Adapted from (20). 
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1.1.5 Brimonidine 
 
Brimonidine (see figure 5 for molecular formula) is an alpha2-adrenergic agonist 
and one of the most used anti-glaucoma drugs. Moreover,  several studies have 
suggested that brimonidine may have additional neuroprotective effects on the optic 
nerve (12).   
 
Brimonidine is rapidly absorbed and well distributed in the eye and its systemic 
metabolism is extensive, in humans, first it is metabolized primarily by the liver. The 
urinary excretion is the major route of elimination of the brimonidine and its metabolites, 
(approximately 87% of an orally-administered dose are eliminated within 120h, being 
74% through urine). Topically administered daily ophthalmic brimonidine is indicated for 
IOP reduction in patients with ocular hypertension and/or open angle glaucoma (OAG). 
Generally, brimonidine is administered as topical eye drops between 2 to 3 times per 
day (7) (8). Brimonidine has been evaluated extensively for ocular and systemic toxicity 
in several animal models, as required to support a new drug application (NDA). Ocular 
(0.08-0.8%, twice daily) and systemic (0.1-2.5 mg/kg/day by oral/diet) administration for 
up to one year produced no organ toxicity, despite plasma levels of 4 to 118 times the 
systemic exposure in humans following ocular administration with 0.2%. Studies have 
shown no oncogenic or teratogenic activity, nor adverse effects on fertility and 
reproduction. These results indicate that brimonidine is nontoxic and safe. In addition, 
several clinical studies have determined that brimonidine has ocular hypotensive efficacy 
in a lower concentration than clonidine (first relatively selective alpha2-adrenergic 
agonist) or apraclonidine (8) (22). 
 
 
 
Figure 5 -  Chemical structure of brimonidine. 
 
9 
1.1.6 Graphene oxide nanosheets 
 
Graphene, a two-dimensional nanomaterial consisting of sp2 hybridized carbon 
atoms, is a basic building block for graphitic materials with other dimensionalities. Given 
its large specific surface area, good chemical stability and other excellent properties (in 
particular, electric properties) graphene holds great promise in different areas. GO refers 
to graphene functionalized with oxygen in the form of ether, hydroxyl, carboxyl, and 
epoxy. GO can be used to create barrier layers in multilayer films by trapping molecules 
of interest for controlled release (23) (17) (24) (17).  
One study performed by Paula T. Hammond et al. (17) showed films fabricated 
with the LbL assembly technique, with GO with charged functional groups and PBAE, 
which delay the drug release from less than one hour to 30 or even 90 days, depending 
on the number of bilayers of functionalized GO in the LbL architecture (17). GO can form 
stable dispersions in water because of its high oxygen-containing groups. Conversely, if 
the oxygen functionality is removed by chemical reduction to yield graphene, this  
aggregates and can  precipitate due to the π-π* interactions between the conjugated 
nanosheets of graphene (25). 
 Regarding toxicity issues, GO in doses of less than 20 μg/mL is toxic to human 
fibroblast cells, in doses higher than 50 μg/mL, some cytotoxicity arises, such as 
decreasing cell adhesion, inducing cell apoptosis, entering lysosomes, mitochondrion, 
endoplasm, and cell nucleus. The possible mechanism of GO’s cytotoxicity is the 
following: the GO in the medium bind with the surface of human cells, providing a stimuli 
signal to the cells. The signal is transduced inside the cells and the nucleus leading to 
down-regulation of adhesion-associated genes and corresponding adhesive proteins. 
This results in a decrease in cell adhesion and cause cells to detach, float, and shrink in 
size. GO enters into the cytoplasm by endocytosis pathway, mainly located in the 
lysosomes, mitochondrion, endoplasm and cell nucleus, where it may disturb the course 
of cell energy metabolism and gene transcription and translation, and even result in cell 
apoptosis or death (26) (17). 
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1.1.7 Poly (ß-amino esters)  
 
Poly(ß-amino esters) (PBAE) (see figure 6 for chemical structure) are a class of 
biodegradable polymers (27), which are degradable by hydrolysis. PBAE is produced 
through Michael addition polymerization of acrylate and amine monomers (28). 
 
These class of hydrolytically biodegradable polymers can be easily obtained in 
large scale to make a large library of structurally diverse materials. Their hydrolysis 
occurs on the time scale of several hours to a few days, and is largely affected by the 
polymer structure as well as the cellular conditions. Also, some studies have shown that 
the PBAE  degrades faster at pH 7 than at pH 5. (29)(30) PBAE shows low cytotoxicity; 
studies described in references (30) (31) show the biocompatibility and biodegradability 
of this compound. Additionally, it was demonstrated that  and NIH 3T3 fibroblast cells 
incubated with PBAE remain 100% viable, for concentrations of polymer up to 100 μg/mL 
(27). Considering such advantageous properties, in particular the fact that its hydrolysis 
can take from several hours to a few days, the polymer (PBAE) was used in order to 
create a DD system with programmable and sequential release (29)(17). 
 
1.1.8 Cyclodextrin  
 
Cyclodextrins (CD) are cyclic oligosaccharides, the main natural CD (α, ß and γ) 
are constituted of 6, 7 and 8 glucopyranose units connected by α(1,4)-linkages, 
respectively, but larger ones have been also isolated (32). CDs have a hydrophobic 
cavity able to encapsulate multiple molecules, due to their capability to form noncovalent 
inclusion complexes with a large variety of guest molecules (33) (34). These 
characteristics have determined their applicability in different fields. CDs have mainly 
been used in the pharma area, as DD systems to improve the solubility of drugs. 
Furthermore, the properties of CDs can be modulated through chemical modifications. 
Figure 6 - Chemical structure of PBAE. Figure adapted from (27).  
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Also, CDs have been investigated in the highly interesting field of neurodegenerative 
diseases associated with protein misfolding (33).  
The mostly used CD in developing systems to be applied over the eyeball is 2-
Hydroxypropyl-ß-cyclodextrin, since it does not show irritating effects and has improved 
water solubility and may be toxicologically benign (35) (36). Concerning other types of 
CD, the cavity size of α-CD is insufficient for many drugs, γ-CD is expensive, and, in 
general, δ-CD has weaker complex forming ability than conventional CDs. β-CD has 
been widely used in the early stages of pharmaceutical applications because of its ready 
availability and cavity size, which is suitable for the widest range of drugs. Nevertheless, 
low aqueous solubility and nephrotoxicity limited its use especially in parenteral DD (see 
figure 7 for a schematic representation of each cyclodextrin) (34). 
 
CDs have several applications in the eye-care field, especially in the aqueous 
eye drop preparations, to reduce ocular drug irritations and to promote the drug 
permeability by making the drug available in the ocular surface and increasing 
absorption. CDs have shown to be non-toxic to the eye and to be well-tolerated in the 
aqueous/biological medium (34). 
The most widely used approach to study inclusion complexation is the phase 
solubility method, which examines the effect of a solubilizer, CD or ligand, on the drug 
being solubilized, the substrate. The equilibrium binding of drug and CD to form a 1:1 
complex can be represented as:  
Drug + CD ⇌ Drug:CD Complex 
 
The type of CD can influence the complex formation (the cavity size of CD should 
be suitable to accommodate a drug molecule of a particular size) as well as the 
 Figure 7 -  Representation of the cyclodextrin macromolecule (33). 
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performance of drug/CD complexes. Compared with neutral CDs, complexation can be 
better when the CD and the drug carry opposite charges (conversely, complexation may 
decrease when they carry the same charge) (34). 
Figure 8 depicts the dynamic equilibrium for 1:1 (figure 8a) and 1:2 drug–CD 
(figure 8b) complexes. As seen, inclusion complexes may be formed involving the entire 
drug molecule or only a portion of it. Figure 8c presents schemes of how α-, β- and γ-
CD can form inclusion complexes with a specific drug. 
 
 
 
 
 
 
 
 
 
 
1.2 Motivation 
 
The principal motivation for this research deals with the development of DD LbL 
films for glaucoma treatment able to release precise amounts of drug and at precise 
periods of time. The conventional method consists on eye drops administration, for which 
only 20% of the active drug in one droplet achieves the ocular anterior chamber, the 
remaining being drained through the nasolacrimal duct (13). Another problem relates to 
  Figure 8 - Schematic illustration of the association of free cyclodextrin and drug to form drug-CD 
complexes. A: 1:1 drug-CD complex; B: 1:2 drug-CD complex; C: a) α-CD; b) ß-CD; c) δ-CD. 
Adapted from (1). 
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the patient non-compliance, since half of glaucoma patients do not use their ophthalmic 
medication properly (37). 
A potential alternative solution in glaucoma treatment could be the use of 
intralocular devices. This thesis developed DD films that can be work as coatings of an 
intraocular device, incorporating the same drug as that used in the conventional 
therapeutics.  
 
1.3 Objectives and research overview 
 
The objective of this research was to develop biocompatible multilayer films with 
DD function that can coat intraocular devices in order to be used in glaucoma treatment. 
The main goal was to fabricate films composed of layers of brimonidine, GO and PBAE. 
The first strategy consisted in preparing GO functionalized with ß-cyclodextrin to 
control the number of cyclodextrins contained in the film. However, the syntheses were 
not well succeeded and a second approach was adopted consisting in the preparation 
of layers of brimonidine encapsulated in 2-Hydroxypropyl-ß-cyclodextrin. The complex 
was then deposited over a bilayer of charged GO by self-assembly. Thus, the DD films 
were composed by alternated layers of brimonidine encapsulated with 2-Hydroxypropyl-
ß-cyclodextrin and two types of layers, PBAE and charged GO to control the rate of 
released brimonidine. The films growth was followed by atomic force microscopy (AFM) 
and UV-Vis absorption spectroscopy. Three types of films, where layers of brimonidine 
were intercalated with different sequences of layers (PBAE/GO+/GO-), (PBAE/GO-/GO+) 
and (GO-/GO+) were prepared. 
The efficiency of DD films in terms of brimonidine release was followed by UV-
Vis absorption spectroscopy and by High Performance Liquid Chromatography (HPLC).  
 
1.4 Thesis Outline 
 
 
This thesis is divided in four main chapters. In the Introduction, it is presented the 
current state of the art, regarding the inherent complications of glaucoma and its 
treatments. The biomedical developments that have taken place in order to treat this 
disease and its complications are also described. Chapter 2 describes the materials used 
to prepare de drug delivery films, the methods and characterization techniques used to 
characterize the films and the kinetic of brimonidine released. Chapter 3 presents the 
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results of the drug delivery films growth and its characterization by Ultraviolet-visible 
spectroscopy (UV-Vis) and by Atomic Force Microscopy (AFM). Chapter 4 comprises 
the kinetics of brimonidine release and its characterization by UV-Vis, and HPLC. 
Chapter 5 describes the main conclusions of this work and Chapter 6 describes 
proposals of future works in order to keep going this thesis. An Appendix section is 
presented at the end with additional results.  
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Chapter 2 - Materials and Methods 
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2. Materials and Methods 
 
2.1 Materials 
 
2.1.1 Negatively charged graphene oxide  
 
Negatively charged GO was purchased from Graphenea, as an aqueous 
dispersion of nanosheets with a concentration of 0.5 mg/mL and 4mg/mL (see figure 9). 
 
2.1.2 Graphene Oxide functionalized with cyclodextrin 
 
The first approach was to synthetize GO functionalized with the ß-cyclodextrin, 
following a method developed by Wang et al. (23). This process includes two steps, the 
first step was the preparation of graphene with epoxi groups to anchor CD (GO-O) and 
the second one, the preparation of GO-β-CD. This study also refers to a preparation of 
the GO by the Hummers method (38), but in this thesis, it was used the commercial GO. 
The negatively charged nanosheets were purchased as an aqueous dispersion with a 
concentration of 4 mg/mL. The method described by Wang et al. (23) is as follows: 10 
mL of graphene oxide aqueous dispersion with a concentration of 4.0 mg/mL (pH=2.40) 
were mixed with 15 mL of distilled water and the mixture is homogenized in an ultrasonic 
bath for 10 min  The pH is then adjusted to 9.44 with drops of an aqueous solution of 
NaOH 10%.  
Figure 9 -  Chemical structure of negatively charged graphene oxide. 
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Next, 1.5 mL of epichlorohydrin (ECH) from Sigma Aldrich was added dropwise 
and this solution was stirred at room temperature for 30 min. At pH of 9.44 most hydroxyl 
groups in GO suffer deprotonation and a nucleophilic attack can occur to the C-Cl group 
in epichlorohydrin, the anchoring group. This reaction must be performed under alkaline 
conditions through a reaction between ECH and the –OH on the graphene. Then the 
temperature was gradually increased to 60ºC and the mixture was stirred magnetically 
at 60ºC for 3h. It is important to maintain the initial stage of the reaction at the room 
temperature to assure that only a nucleophilic reaction occurs, instead of an elimination 
reaction, which is favored by high temperatures. 
The final volume obtained of the GO-O solution was 28 mL. Next, a dialysis was 
performed using a cellulose membrane (Sigma Aldrich), that has a cut off of about 12 
000-14 000 Da. Before the dialysis, the membrane was washed for one day under 
running water, to remove the protective glycerol layer.  
The dialysis was performed during several days in a large volume of water which 
was replaced every day. After the dialysis, 30 mL of a freshly prepared carbonate buffer 
solution with pH=10.00 prepared from two solutions of 2 mL of 0.2M NaHCO3 
(1.68g/100mL) and 23 mL of 0.2M K2CO3 (2.76g/100mL) was added. The final pH was 
9.97 (VFinal=60mL). 0.500 g of ß- Cyclodextrin was added to the solution and the mixture 
was stirred magnetically at 60ºC for 3 hours. Figure 10 represents a scheme of the 
preparation of the GO functionalized with CD. 
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Unfortunately, the results obtained did not comply with those reported in 
literature, since by comparing the infrared spectrum of the G-ß-CD after the above 
described treatment and the infrared of pristine GO-O, no significant changes were 
observed. Figure 11 to figure 13 describes the results obtained compared with the 
literature (23).  
It was also performed NMR to the washing waters of the dialyses performed on 
each step of the reaction to assure that GO-O was not left behind during that purification 
step. It is very likely that the used GO-O had a low density of –OH groups and therefore, 
for that reason, the degree of functionalization obtained is also low. To circumvent this, 
will be proposed that in  future work, GO-O should be synthetized by Hummers method 
(38), as reported, instead of using commercial GO. 
 
Figure 10 - Schematic illustration of the preparation of ß-CD functionalized with graphene 
oxide. Adapted from (23). 
 
19 
 
 
 
 
 
Figure 11 - Infrared spectrum of dried GO obtained in step GO deposited over a KBr pellet. 
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 Figure 12 -  Infrared spectrum of dried GO-O obtained in step GO-O deposited over 
a KBr pellet. 
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Figure 13 - Infrared spectrum of dried GO-ß-CD obtained in step GO-β-CD deposited 
over a KBr pellet. 
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2.1.3 Synthesis of positively charged graphene oxide  
 
The positive nanosheets of GO were prepared by reducing the negative GO (in 
aqueous dispersion with a concentration of 0.5 mg/mL) and linking amine groups to the 
carboxylic acids present at the edges of the GO (see figure 14). A method developed by 
Hwang et al. (39) was used to prepare positively charged GO.  
Under this method, 50 mL of negative GO solution were mixed with 0.625 g of N-
ethyl-N’-(3-dimethylaminopropyl)carbodiimide methiodide (EDC) (Sigma Aldrich) and 
with 5 mL of ethylenediamine (Sigma Aldrich). 
 
 
 
 
2.1.4 Poly (ß-amino ester) 
 
The PBAE (see figure 5 for molecular formula) used in the thesis was previously 
synthetized by the Organic Electronics group of IT following the protocol described by 
Lynn, et al.: 3.28 g of 4,4’-trimethylenedipiperidine (S1) (97% purity, Sigma Aldrich, CAS 
number 16898-52-5) and 2.87 mL of 1,4-butanediol diacrylate (S2) (99% purity, Alfa 
Aesar, CAS number 1070-70-8) were mixed in dry tetrahydrofuran (THF) (previously 
distilled). The copolymerization was carried out at a temperature of 50°C, during 48 
hours. The polymer PBAE was purified through repeated precipitations into diethyl ether. 
The final polymer was then dried under vacuum overnight. The structure of the final 
product was confirmed by Nuclear Magnetic Resonance Spectroscopy (NMR) (27).  
Figure 14 - Schematic representation of the reaction to obtain positively charged graphene 
oxide from negatively charged GO. The two GOs will be alternated by the LbL method (52). 
 
23 
2.1.5 2-Hydroxypropyl-β-cyclodextrin 
 
2-Hydroxypropyl-β-cyclodextrin (HP-β-CD) (figure 15), the host used to 
encapsulate the brimonidine, was purchased from Sigma-Aldrich (CAS number: 128446-
35-5, Mw=1460 g.mol-1.) and it was used as received.  
 
 
 
 
 
 
 
 
 
 
2.1.6 Brimonidine 
 
Brimonidine is an ocular drug usually used in glaucoma treatment, used to 
decrease the intraocular pressure. Brimonidine was supplied from Sigma Aldrich 
(Mw=292.13 g.mol 1, CAS number 59803-98-4).  
 
2.1.6.1 Brimonidine encapsulation 
 
 
Complexes of brimonidine encapsulated in (HP-β-CD) were prepared by 
dissolving 2.25 g of HP-ß-CD (maximum solubility is 45% (w/v)) in 3 mL of distilled H2O, 
the solution was left to stir for 2 hours. Then 4 mg of brimonidine (maximum solubility: 
0.8 mg/mL) was added and the volume was completed to 5 mL with distilled H2O. This 
solution was stirred for 12 hours protected from light. As figure 16 shows, the absorption 
spectrum of the brimonidine solution shows an absorption band at 250 nm which is 
characteristic band of the complex HP-ß-CD (HP-ß-CD+Brim).  
Figure 15 - Chemical representation of the 2-hydroxypropyl-β-cyclodextrin molecule. 
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Figure 17 shows an UV-Vis absorption spectra comparing a solution of 
brimonidine in PBS and the solution of brimonidine after film immersion in PBS solution. 
 
 
Figure 16 - UV-Vis absorption spectrum of brimonidine encapsulated in HP-ß-CD. 
(Concentration = 2.74 mM).   
 
(nm) 
Figure 17 - UV-Vis absorption spectra of Brimonidine solutions: after dialyses and in 
standard PBS 28.5 µM. 
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2.2 Characterization techniques and DD films preparation  
 
This section describes the techniques that were used to characterize the films 
and details the method employed to prepare the multilayer DD films.  
 
2.2.1 Ultraviolet-visible absorption spectroscopy  
 
UV-Vis  spectroscopy is a technique, that comprises to absorption spectroscopy 
or reflectance spectroscopy in the ultraviolet-visible spectra region. 
When radiation interacts with matter, several processes can occur, including 
reflection, scattering, absorbance, fluorescence/phosphorescence and photochemical 
reaction. Since light is a form of energy, absorption of light by matter causes the energy 
content of the molecules (or atoms) to increase (40). 
The Lambert-Beer's law, is a quantitative way to determine concentrations of an 
absorbing species:  
I = I0⋅e
−μ⋅l                                  Equation (1) 
where I0 is the initial intensity of the radioactive source, I is the remaining beam 
intensity, μ is the linear attenuation coefficient and l is the thickness of the absorber (41).  
The maincomponents of a spectrophotometer are (40) (42), a source of radiant 
energy; a wavelength selector, that isolates a limited region of the spectrum; one or more 
sample containers; one or more detectors to measure the intensity of radiation; other 
optical components, such as lenses or mirrors; a computer, to process the signal. With 
this technique, absorption spectra of the DD films were obtained to follow the film growth 
after the formation of each bilayer and to quantify the brimonidine release. The 
absorption spectra of the films were obtained using quartz substrates. A Cecil Aquarius 
CE 7200 spectrophotometer was used in all experiments (see figure 41 on appendix). 
 
2.1.2 Atomic Force Microscopy 
 
Atomic force microscope (AFM) is one of the most important technique for 
morphological studies in biomedical field and it is commonly used to acquire high-
resolution surface topography images (3) (43). AFM was invented in 1986 by Rohrer and 
Binnig (44) and has been used to image surfaces at molecular and nanoscale. 
Furthermore, the AFM is able to study mechanical forces and molecular interactions of 
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adsorbates on surfaces. The basic principle of AFM is based on a sharp tip integrated 
into a flexible cantilever which is brought close with the sample surface and scans the 
sample surface. At this stage, attractive and repulsive forces cause the deflection of the 
cantilever which is controlled by feedback mechanism,  an optical beam apparatus 
detects the cantilever’s deflection which is recorded and analyzed by an electronic 
system (45) (46).  
AFM probes the surface-supported sample by scanning the tip. The tip position, 
which reflects the tip–surface interaction, is monitored by the deflection of a laser beam 
on the cantilever, which is measured by a position-sensitive quadrant photodiode. The 
computer and electronic system then record the cantilever position (Z) at each point of 
the scanned surface (X, Y) (figure 18 demonstrates the apparatus of the AFM) (45). 
 
The AFM can operate in three types of modes, contact (the tip is in continuous 
contact with the surface and it’s very sensitive to each small change on the surface), 
non-contact (the cantilever vibrates and variations from its resonance frequency are 
used to generate images) and intermittent (the cantilever moves rapidly with a large 
oscillation between the repulsive and attractive forces) (see figure 19) (3) (45) (2). 
 Figure 18 - Schematic representation of the AFM apparatus (2). 
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In this work, all the measurements were performed in non-contact mode, in order 
to avoid damaging the studied surfaces. AFM phase contrast microscopy was used to 
detect and quantify changes in composition for each layer of the film (43). The 
topographic images were used to analyze the surface of each monolayer after 
adsorption. The microscope used for all the experiments was a Nano-Observer AFM 
from CSInstruments existing in the Organic Electronics group at Instituto de 
Telecomunicações (see figure 42 in appendix).  
After analyzing the AFM images, it is necessary to optimize the image quality by 
exploring the software facilities and applying an adequate image treatment. The first 
step, called “levelling” is used to remove artefacts which are due to some tilt introduced 
in the sample image, by subtracting a background. This method is called line by line and 
consists in fitting an image profile line with a polynomial equation which is subtracted 
from that image line (47). 
The surface morphology can be the described by several statistical parameters, 
being the amplitude parameters the principal ones for characterizing the surface 
topography. The Root Mean Square Roughness (Rrms) is the most used amplitude 
parameter; it represents the standard deviation of surface heights, and it is expressed 
by equation 2 (47). 
Figure 19 - Tip-sample separation curve illustrating the main interactions during 
AFM scanning (3). 
 
28 
The analyzed surfaces were also characterized using statistical information about 
the grains presented at the surface, through the calculation of the height distributions of 
the grains, considering that the image is constituted by a matrix with z(x,y) of height, with 
N lines and M columns.  
 𝑅𝑟𝑚𝑠	 𝑁,𝑀 = 𝑧 𝑥, 𝑦 − 	𝑧./0(𝑁,𝑀) 345678967    Equation (2) 
 
2.1.3 Nuclear Magnetic Resonance  
 
NMR is based on the interaction of magnetic moments of nuclei of various atoms 
with magnetic fields, this phenomenon was first described in 1946 by Bloch and Purcell. 
The magnetic moment of nuclei is associated with a nuclear spin, which is a form of 
angular momentum possessed by these nuclei. The value of nuclear spin is defined by 
a spin number,  atoms with an odd mass number such as 
1
H, 
31
P and 
13
C possess the 
quantum property of ‘‘spin’’ and behave as dipoles aligning along the axis of an applied 
magnetic field (48) (49). 
In this work, it was performed NMR-1H (300 MHz, CDCl3) of the wash solution 
obtained in the synthesis of GO-O and GO-β-CD (the results obtained are shown in 
appendix on figure 45). 
 
2.1.4 Infrared spectroscopy 
 
Infrared (IR) spectroscopy is one of the most common and widely used 
spectroscopic techniques, very useful to identify functional groups and molecular 
structures (50) (51). Basically, it is an absorption spectroscopy which probes samples 
absorption of the infrared electromagnetic radiation. In this work, it was determined 
Fourier-transform infrared (FTIR) absorption spectra, obtained by transmission, of the 
GO, GO-O and GO-β-CD in each step on the synthesis, it was used a Bruker 
spectrometer. 
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2.1.5 DD Films Preparation 
 
Firstly, all the used substrates were washed in «piranha solution», this process 
consists of immersing the sample in a mixture of H2SO4 and H2O2 to oxidize surface 
contaminants (i.e. to remove any organic contamination), then washed with copious 
amounts of tap water and finally they were submitted to a sequence of washes with 
distilled water, propan-2-ol HPLC, and again distilled water. The substrates were then 
dried with a nitrogen gas flow. 
In order to improve the adsorption of the first layer of PBAE, it was necessary to 
increase the hydrophilicity of the substrate surface (52). The substrates were treated with 
oxygen plasma in a vacuum chamber Plasma Prep 2 from, Gala Instrument (see figure 
43).  The optimum time of absorption was previously studied (53), each substrate was 
immersed for 5 minutes onto each solution. 
After the treatment with oxygen plasma, the substrate was immersed into a 
solution of PBAE. After remaining in this solution for a certain period of time, the 
substrate was rinsed with an aqueous solution of sodium acetate (with pH adjusted to 
5.0) in order to remove non adsorbed molecules (only physically adsorbed) and then it 
was dried with a nitrogen gas flow. After this sequence, a monolayer of PBAE is formed. 
Then the substrate was immersed in the solution of positively charged GO, during a 
certain period of time and washed again in sodium acetate (pH=5.0). It was, dried with 
nitrogen, and the substrate was immersed again, now into a solution of negatively 
charged GO, during a certain period of time, and washed in sodium acetate (pH=5.0). 
After drying with nitrogen, finally the substrate was immersed into a solution containing 
brimonidine encapsulated with HP-ß-CD, during a certain period of time, washed in 
sodium acetate (pH=5.0) and dried with nitrogen. After each added layer, an UV-Vis 
measurement of the substrate was performed. For the film with the inverted bilayer of 
GO, the procedure was the same, only changing the order of immersion on the GO 
aqueous dispersions. 
This process represents a complete cycle of the LbL assembly, forming one 
bilayer of (PBAE/GO+/GO-/HP-ß-CD+Brim) or (PBAE/GO-/GO+/HP-ß-CD+Brim). The 
deposition cycle was repeated the number of times equivalent to the number of intended 
bilayers.  
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2.1.6 High Performance Liquid Chromatography  
 
HPLC represents the culmination of the modernization of Liquid Chromatography 
(LC) and is currently one of the most used separation techniques in analytical chemistry, 
due to its advantageous characteristics, such as high sensitivity and automation (54).  
The apparatus of a HPLC (see figure 20) consists of a system of distribution of mobile 
phase (reagent reservoir and pumping system), an injector which can be automatic or 
not, the column where the analytes are separated, a detector and a data acquisition 
system (55) (56). 
 
 In addition, most recent HPLC systems also contain a degassing system to 
remove gases dissolved in the solvents and which may affect the performance of the 
detector. The pumping system of an HPLC apparatus is capable of pumping the mobile 
phase at a specific flow rate and at high pressures so as to be able to traverse the 
column. From this system, there are also devices that allow to control the flow and to 
program the proportion of each of the solvents used in the mobile phase, in case of a 
gradient elution (56) (54). The sample, dissolved in the mobile phase, goes to the 
chromatographic column, where the various analytes of interest are separated based on 
mechanisms of interaction between the mobile phase and the stationary phase. 
Nowadays there is a huge variety of fillers for the HPLC column, that will determine the 
success of the analytical method in terms of efficiency and selectivity in separating the 
species of interest. The analytes, according to their affinity for the stationary phase, are 
eluted from the column and pass through a detector, which emits a signal to a computer 
software. The signal is plotted as a function of the retention time, designated by 
chromatogram. The identification of the analytes is done based on the retention times 
and, from the area of the respective peaks, it is possible to quantify them (56) (4). 
Figure 20 - High Performance Liquid Chromatography apparatus (Adapted from (4)).  
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The HPLC analysis were performed at Instituto Superior de Engenharia de 
Lisboa, that kindly supplied the equipment to carry out these experiments. It was used 
an Elite LaChrom system (see figure 44 in appendix) with the conditions detailed on table 
1. This study was based on the article found on the literature (57). 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Parameters Conditions 
Mobile Phase composition Ammonium acetate (pH 5.0, 0.01M) - 
Methanol (40:60 v/v) 
Flow 1 mL/min 
Injection volume 20 μL 
Wavelength 254 nm 
Oven Temperature 30 ºC 
Run time 10 minutes 
Table 1 - Chromatographic conditions used on HPLC. 
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3. Growth of drug delivery films 
 
This chapter addresses the growth of DD films prepared by LbL technique and 
monitorized by AFM and UV-Vis spectroscopy. The AFM was used to analyze the 
evolution of layers’ morphology in order to detect imperfections during the film growth. 
These results were accompanied with UV-Vis spectroscopy analysis of all film layers. 
The following sections describe such results.  
 
3.1 Atomic Force Microscopy analysis of DD films  
 
The AFM technique was applied to characterize six different surfaces, in order to 
verify if the film was well deposited on each layer and to detect possible defects related 
with contaminations or roughness irregularities. Ideally, each new layer should fully coat 
the previous one. However, interdifusion between consecutive layers can occur leading 
to features that may be detected by AFM analysis, mainly through the phase images. 
Phase images are obtained during the surface scanning together with the 
topography images; they give information about the surface homogeneity in terms of 
their composition. In case of occurring interdifusion between consecutive layers, the 
surface will be composed of more than one compound and this will result very likely as 
a contrast in phase images. Films with (PBAE/GO+/GO-/HP-ß-CD+Brim) where analyzed 
and all measurements were performed in non-contact mode using silicon tips. The 
images have a resolution of 256x256 pixels and a scanned area of 1x1 μm
2
. Additional 
images with 2x2 μm2 are presented in appendix (table 5 and 6). Tables 2 and 3 show 
the topography and phases images of all film layers and a profile line in order to 
characterize the roughness of each layer. It was used the same adsorption time 
described in section 2.1.5. 
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Table 2 - AFM images of prepared LbL films with different layers. 
PBAE – Scan size 1 µm 
Topography Phase Profile line 
  
 
PBAE/GO+/GO- – Scan size 1 µm 
Topography Phase Profile line 
  
 
PBAE/GO+/GO-/HP-ß-CD+Brim – Scan size 1 µm 
Topography Phase Profile line 
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Table 3 - AFM images of prepared LbL films with different layers. 
(PBAE/GO+/GO-/HP-ß-CD+Brim/PBAE) – Scan size 1 µm 
Topography Phase Profile line 
   
PBAE/GO+/GO-/HP-ß-CD+Brim/PBAE/GO+/GO- – Scan size 1 µm 
Topography Phase Profile line 
  
 
PBAE/GO+/GO-/HP-ß-CD+Brim/GO+/GO- – Scan size 1 µm 
Topography Phase Profile line 
  
 
 
 
From table 2, it can be observed that the topography and phase images of PBAE 
surface reveal the existence of grains, also evidenced in different tip-surface interactions, 
i.e., when scanning the darker regions, the tip tilt is different from that in the bright ones. 
Such contrast in the phase image suggests the existence of two materials at the surface. 
Considering the fabrication approach of the films, the observed darker regions may 
correspond to salt grains resulting from the wash solution used after layer formation.   
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The AFM images of (PBAE/GO+/GO-) layer show a smoother surface compared 
with that of PBAE, exhibiting a Rrms of approximately 3.19 nm determined for the image 
with the scan size of 1 μm. The topography image presents straight lines which could 
correspond to GO nanosheets overlapping. The respective phase image shows a slight 
contrast between the grains and the background which can suggest the presence of salts 
resulting from the wash solution. Given the significant differences between the images 
of this film with those of PBAE film along all the extension of the scan, it can be inferred 
that the GO layer fully covers the previous PBAE layer.   
 The topographic and phase images of the (PBAE/GO+/GO-/HP-ß-CD+Brim) film, 
show a smooth surface with a Rrms of 1.97 nm. However, the phase image shows that 
the elevated line shown in the topographic image has a darker color compared with the 
background. This region can be related with GO within the previous layer which is not 
fully covered by brimonidine.    
Table 3 shows AFM images of a PBAE layer adsorbed over the (PBAE/GO+/GO-
/HP-ß-CD+Brim). As it may be observed, the surface is smoother (Rrms=2.73 nm) than 
that found for when PBAE is deposited on bare glass (Rrms of 3.64 nm). Also, the phase 
image suggests that the previous graphene layer is fully covered. The following images, 
for the bilayer of GO+/GO-  show also a rougher surface (Rrms=7.47 nm) compared with 
the previous graphene bilayer (Rrms=3.19 nm).    
Another film with (PBAE/GO+/GO-/HP-ß-CD+Brim/GO+/GO-) structure was 
analyzed by AFM in order to analyze the GO surface when GO is deposited over HP-ß-
CD+Brim instead of PBAE as in the previous film. In the (PBAE/GO+/GO-/HP-ß-
CD+Brim/GO+/GO-) film the surface shows a Rrms of 2.71 nm revealing to be smoother 
than the surface of (PBAE/GO+/GO-/HP-ß-CD+Brim/PBAE/GO+/GO-) (Rrms=7.47 nm).  
 
3.2 UV-Vis spectroscopy analysis of DD films 
 
 The LbL films growth was studied by UV-Vis spectroscopy to characterize the 
kinetics of adsorption. Thus, the films were grown on quartz substrates which were firstly 
cleaned in a «piranha» solution to remove organic contaminants from the surface. The 
subtracts were treated with oxygen plasma in a vacuum chamber to improve 
hydrophilicity of the surface, as previously referred on section 2.1.5. 
Since this is a strongly oxidizing solution, it will also hydroxylate the substrate 
surface, adding -OH groups, and making it highly hydrophilic; figure 21 shows 
schematically the effect of «piranha» on quartz (58) (59) (5). 
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Three types of films were analyzed in terms of their growth and they are 
schematized in figure 22 a, b and c. Films with and without PBAE where compared in 
order to analyze the influence of this polymer in the film growth and films with inverted 
charged graphene layers were also compared.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 21 - Effect of piranha treatment on quartz substrates (5). 
b a 
c 
Figure 22 - Schemes of structures of a) Film with PBAE/GO+/GO-/HP-ß-CD+Brim; b) Film with PBAE/GO-/GO+/ 
HP-ß-CD+Brim; c) Film without intercalated PBAE. n= number of cycle layers.  
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3.2.1 DD films with graphene oxide films and with PBAE   
 
Figure 23 shows the absorption spectra accompanying the growth of a film 
composed of eleven groups of (PBAE/GO+/GO-/HP-ß-CD+Brim). An UV-Vis spectrum 
was obtained after GO+, GO- and HP-ß-CD+Brim layers formation in order to monitorize 
the film growth step-by-step. As observed, the spectra are sequential in intensity, except 
for the first two layers where the spectra overlap. This behavior can be due to 
imperfections in the film related with incomplete layer formation.  
Through the AFM analysis of the topographic and phase image of 
(PBAE/GO+/GO-/HP-ß-CD+Brim) films it was observed that the thickness of HP-ß-
CD+Brim layers is not enough to cover the previous graphene bilayer. This incomplete 
coverage can affect the film growth. However, figure 23 indicates that absorption 
increases sequentially with the number of (PBAE/GO+/GO-/HP-ß-CD+Brim) group 
layers.  
 
 
 
 
 
 
Figure 23 - Absorption spectrum of the layers presented in a film with eleven groups of (PBAE/GO+/GO-
/HP-ß-CD+Brim) obtained after each layer deposition. 
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 Another type of films that were prepared and studied consisted of films where the 
order of GO layers was inverted, i.e. films with (PBAE/GO-/GO+/HP-ß-CD+Brim) groups.  
The objective was to observe the possible influence of the GO charge in the brimonidine 
absorption.  
 Figure 24 shows the evolution of the spectra obtained after each layer deposition 
for a film composed by eleven groups of (PBAE/GO-/GO+/HP-ß-CD+Brim).  
 Similarly, to the previous film, the spectra intensity also increases sequentially 
with the film growth. However, and similarly to what was observed for the previous film 
(see figure 23), some spectra sobrepositions occur for the first layers, which can also be 
related with incomplete coverage of the GO surface by the HP-ß-CD+Brim layer.   
 
 
 
 
 
 
3.2.2 DD films with graphene oxide films and without PBAE  
 
Figure 25 shows the absorption spectra obtained when accompanying the growth 
of a DD film without PBAE (film scheme in figure 21c) and with 12 groups of 
(PBAE/GO+/GO-/HP-ß-CD+Brim/GO+/GO-)12. In this case, the spectra indicate that the 
Figure 24 - Absorption spectrum of a film with eleven groups of (PBAE/GO-/GO+/HP-ß-CD+Brim) 
obtained after each layer deposition. 
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growth of layers is not sequential in intensity. In conclusion, the absence of PBAE can 
allow the interdifusion of consecutive layers, thereby causing a disorder in the film 
growth.  
 
 
 
3.3 Growth of DD films conclusion 
  
To conclude this chapter, it is possible to draw a conclusion that the film growth 
in the DD films studied (see figure 22 a) and b)) is constant, and the absorption increases 
sequentially with the number of (PBAE/GO+/GO-/HP-ß-CD+Brim) group layers, and with 
the inverted order of GO layers the behavior is identical. Some sobrepositions occurred 
for the first layers and that could be related with incomplete coverage of the GO surface 
by the HP-ß-CD+Brim layer. For the film (PBAE/GO+/GO-/HP-ß-CD+Brim/GO+/GO-), the 
absence of PBAE can allow interdifusion of consecutive layers, thereby causing a 
disorder in the film growth. 
 
 
 
 
Figure 25 - Absorption spectra of the film with twelve groups (PBAE/GO+/GO-/HP-ß-
CD+Brim/GO+/GO-)12 obtained after each layer deposition.  
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4. Drug Delivery Films Release Kinetics  
 
This chapter describes the brimonidine kinetic release for the films with PBAE 
and graphene where three groups of films were studied: films with GO+/GO-, films with 
inverted graphene charges GO-/GO+ and films without PBAE. The release of brimonidine 
was followed by UV-Vis absorption Spectroscopy and by HPLC.  
 
4.1 Brimonidine release kinetics of films with GO+/GO- 
 
The brimonidine release kinetic was analyzed by using the techniques UV-Vis 
absorption and HPLC. For such analysis, the films were immersed in a phosphate buffer 
saline (PBS) solution which is similar to the biological fluid, in terms of pH (pH=7.4, equal 
to the physiologic pH) and concentration of salts, the temperature of the solution was at 
room temperature. A film with eleven groups of (PBAE/GO+/GO-/HP-ß-CD+Brim) was 
immersed in PBS solution during a total time of 700 hours (approximately 30 days). The 
immersion was controlled step-by-step, immersing the film during small periods and 
changing the PBS after each immersion. 
After each film immersion, the PBS solution was analyzed by HPLC in order to 
evaluate the amount of HP-ß-CD+Brim released to the aqueous environment. To 
determine the brimonidine concentration in each sample, it was necessary to perform a 
calibration curve with standards of different concentrations.  
The graph in figure 26 shows the obtained calibration curve (peak area obtained 
from the chromatograms vs. concentration) using five standard solutions with 
brimonidine concentrations of 4 µg/mL, 10 µg/mL, 15 µg/mL, 20 µg/mL e 24 µg/mL (see 
appendix figures 49 to 53 for the obtained chromatograms). 
 
 
 
43 
 
 
The calibration curve was adjusted with a linear function and expressed by the 
equation (3). This equation allows the calculation of the brimonidine concentration in the 
samples from the peak area of the brimonidine in the respective chromatogram.  
 
 𝑃;</; = 	342873×Brim                       Equation (3) 
 
For example, for the chromatogram represented in figure 27, which has an area 
of brimonidine of 211298 (retention time of brimonidine at 2.113 min, see table 4), will 
have a concentration of 0.616 µg/mL as it is demonstrated by equation (4): 
 𝑃;</; = 	342873×Brim +	 𝐵𝑟𝑖𝑚 = 211298342873 = 0.616 𝜇𝑔𝑚𝐿 
 
Figure 26 -  Linear Regression obtained from the HPLC data. 
Equation (4) 
 
 
44 
 
The area of each peak is calculated by the HPLC software EZ Chrom Lite which 
allows the identification of the peaks and automatically calculates the retention time, 
area, % area and the height of each peak present at the chromatogram, as described in 
the table 4. 
 
 
Retention Time Area % area Height 
2.113 211298 88.00 90.26 
9,917 28824 12.00 9.74 
 
The obtained chromatograms only show the presence of brimonidine, thus 
suggesting that the drug is released from the CD when the film is immersed in the PBS 
solution. The graph in figure 28 shows the evolution of brimonidine concentration as a 
function of time over a total of 30 days (all the HPLC results obtained can be consulted 
on figure 46 on Appendix).   
After 3 hours from the beginning of the desorption study, it is possible to observe 
that the amount of HP-ß-CD+Brim released is approximately 0.63 µg/mL).  
At approximately 50 hours the release of HP-ß-CD+Brim decreases and stays 
relatively stable until approximately 160 hours of immersion time, when an increase of 
HP-ß-CD+Brim released is observed. This release decreases a little again and stays 
stable until approximately 600 hours when it is possible to observe another increase of 
HP-ß-CD+Brim concentration (about 0.74 µg/mL). 
t (minutes) 
P a
re
a Brimonidine peak 
at 2.113 min 
Figure 27 - Chromatogram obtained from the analysis of PBS solution after film immersion. 
 
Table 4 - Data obtained from the analysis of a chromatogram. 
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After almost 700 hours (about 28 days) of immersion time, the amount of 
brimonidine released is very low comparing to the other results, this may be due to the 
fact that the film at this stage is composed of only the first layer of HP-ß-CD+Brim.  
 
 
The film that was immersed in the PBS solution were also analyzed by UV-Vis 
spectroscopy to quantify the number of layers that remained in the film. This analysis 
was however influenced by the salts from the PBS solution which deposited in the film 
surface. The salts deposition caused scattering effects in the spectra, causing the 
increase in spectrum intensity; the salts lead to light dispersion that reduces the light 
transmission and appears as absorption. This salt accumulation was visible even by 
naked eye. For this reason, only a few spectra were considered and compared with the 
spectra before the film immersion (more spectra are shown in appendix on figure 47). 
From figure 29 it is possible to observe that the maximum of the spectrum of the 
film after 3 hours of immersion in the PBS solution is coincident with that of the spectrum 
of the film with (PBAE/GO+/GO-)11 layers before immersion. This result suggests that the 
HP-ß-CD+Brim layer was released to the PBS solution and that after 3 hours the film 
keeps its 11 group layers.  
Figure 28 - Concentration of brimonidine released to the PBS solution, obtained from HPLC, 
from a film composed of eleven groups of (PBAE/GO+/GO-/HP-ß-CD+Brim) as a function of the 
immersion time. 
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According with the other spectra, plotted in figure 30, between the beginning of 
desorption and 50.75 hours later, the group of layers 11, 10 and 9 were desorbed and 
the film keeps eight groups of layers (PBAE/GO+/GO-/HP-ß-CD+Brim). At this time, the 
spectrum of the film with the 8th layer of HP-ß-CD+Brim is similar to that of the same film 
after 50.75 hours of immersion. Also, the 7th layer of GO+ represented by the blue line is 
similar to the spectrum of the film after 88.25 hours of immersion. 
 
 
Figure 29 - Spectra of film after 3h min of immersion and spectra of film before 
immersion with (PBAE/GO+/GO-)11 
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After 162.25 hours of immersion, the film has a spectrum that is coincident with 
that of the 6th layer of HP-ß-CD+Brim, as shown in figure 31. The monitorization of 
kinetics continued for more than 25 days (t= 621.75 hours) for which it was possible to 
observe that the spectrum at 621.75 hours is coincident with the spectrum of the 5th layer 
of HP-ß-CD+Brim, i.e. the (PBAE/GO+/GO-)6 was desorbed from the film (see figure 32). 
After 644.75 hours of immersion, it can be concluded that the (PBAE/GO+/GO-
)5/(PBAE/GO+/GO-)4 were desorbed from the film and the substrate is on the 3rd layer of 
the complex HP-ß-CD+Brim since the spectrum obtained at this moment is almost 
coincident with the spectrum of the 3rd layer of HP-ß-CD+Brim.  
Almost 28 days after the beginning of the desorption study, all GO layers were 
desorbed; the spectrum acquired is coincident with the spectrum obtained for the film 
with the 1st layer of HP-ß-CD+Brim. 
 
Figure 30 - Spectra of a film after 50.75 h and 88.25 h of immersion and comparison with the 
spectra films before immersion with (PBAE/GO+)7 and (PBAE/GO+/GO-/HP-ß-CD+Brim)8 
structures. 
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Figure 31 -  Spectra of the film after 162.25 h of immersion and of the film before 
immersion and with (PBAE/GO+/GO-/HP-ß-CD+Brim)6 structure. 
Figure 32 -  Spectra of the film after 621.75h, 644.75h and 663.75h of immersion and spectra of films 
before immersion with (PBAE/GO+/GO-/HP-ß-CD+Brim)5, (PBAE/GO+/GO-/HP-ß-CD+Brim)3, 
(PBAE/GO+/GO-/HP-ß-CD+Brim)1 structure. 
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Figure 33 depicts the brimonidine release and the progressive dessorption of all 
layers. Each blue circle represents the layers that remained in the film at a determined 
time (t). 
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Figure 33 - Schematic representation of brimonidine release kinetics with the evolution 
of the remaining layers in the film after immersion in the PBS solution
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4.2 Brimonidine release kinetics of films with GO-/GO+ 
 
In order to evaluate the interaction between the graphene charges and 
brimonidine surface, a film with inverted graphene charges was made. Hence, a film 
composed of eleven groups of (PBAE/GO-/GO+/HP-ß-CD+Brim) was immersed in a PBS 
solution to follow the brimonidine kinetic release.  
Similarly, to the previous studies, this film was also monitorized by UV-Vis 
spectroscopy and the spectra were compared with those obtained during the film growth. 
In order to compare with the film described in previous section where the charged layers 
were inverted (GO+/GO-). In this study salt accumulation was visible even by naked eye. 
For this reason, only a few spectra were considered and compared with the spectra 
before the film immersion (more spectra are shown in appendix on figure 48). 
The drug release monitoring followed the same method, by immersing the film 
during small periods until a total immersion time of about 30 days. From the results 
(Figure 34) it can be concluded that between the beginning of the experiment and 2 
hours and 25 minutes of immersion time, the 11th group (PBAE/GO-/GO+/HP-ß-
CD+Brim) was desorbed from the substrate, since the spectrum of the film after 2 hours 
and 25 minutes of immersion is similar to the spectrum of the film with 10 groups of 
(PBAE/GO-/GO+/HP-ß-CD+Brim). 
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As shown in figure 35, after 16 hours of immersion time, the spectrum recorded 
for the film is coincident to the spectrum of the film with (GO+)8 layers. In conclusion, after 
16 hours of immersion in PBS solution, all the layers in the 10th (PBAE/GO-/GO+/HP-ß-
CD+Brim) were desorbed, and the 9th layer of HP-ß-CD+Brim was also desorbed from 
the film. 
Figure 34 - Spectrum of the film after 2h25 min of immersion and spectrum of a film before 
immersion with (PBAE/GO-/GO+/HP-ß-CD+Brim)10 structure. 
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As it may be concluded from figure 36, after 23 hours of immersion time, the 
layers of 8th and 9th groups desorbed from the film, since the spectrum of the film obtained 
after 23 hours of immersion in PBS is similar to that obtained for the film with the 7th layer 
of HP-ß-CD+Brim.  
The following layer of HP-ß-CD+Brim was released to the solution after 3h45 min, 
as it is indicated in the graphic. The monitorization of the release continued during more 
than 2 days (54h54min). Figure 36 shows that spectrum obtained after this time of 
immersion is coincident with that obtained for the film with a 7th layer of GO negatively 
charged.  
Figure 35 - Comparison between the absorption spectra of film with (PBAE/GO-/GO+/HP-
ß-CD+Brim)8 layers and after PBS immersion during 16h. 
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Figure 37 shows the spectrum of the film immersed in PBS during more than 16 
days (total of 393 hours of immersion time). This spectrum is coincident with the 
spectrum of the 6th layer of GO+, meaning that the 6th layer of HP-ß-CD+Brim was totally 
desorbed from the film at this stage. By analyzing figure 38, it can be concluded that after 
almost 25 days of immersion time (595 hours) the 6th (PBAE/GO-/GO+/HP-ß-CD+Brim) 
group were desorbed from the film, since the spectrum obtained at this time has almost 
the same maximum intensity as the spectrum of the film with 4 groups of (PBAE/GO-
/GO+/HP-ß-CD+Brim) and terminating in (PBAE/GO-), indicating that GO+ and HP-ß-
CD+Brim in the 5th layers were desorbed from the film. 
To conclude the monitorization of the brimonidine kinetics release, at 763 hours 
of immersion time (more than 1 month) the spectrum obtained is coincident with the 
spectrum of the film with 3 layers of HP-ß-CD+Brim, indicating that the group (PBAE/GO-
/GO+/HP-ß-CD+Brim)5/PBAE/GO-/GO+/HP-ß-CD+Brim)4 were desorbed from the film. 
The monitorization was stopped at this stage, because after, the spectra showed only 
noise and could not be compared with the spectra of the films during growth. From these 
results, it could be concluded that after 30 days all layers of the film were desorbed.  
Figure 36 - Spectrum of film after 23h; 54h54 min of immersion and spectrum of film 
before immersion with the (PBAE/GO-/GO+/HP-ß-CD+Brim)7 structure. 
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By comparing this film desorption with that of the film described previously on 
section 3.2 (see figure 22b for film composition), it is found that the brimonidine 
desorption follows a similar behavior, although the complete release of all the layers of 
brimonidine and the GO is longer. 
 
 
 
 
 
 
 
 
 
 
 
Figure 37 - Spectrum of film after 393h of immersion and spectrum of film before 
immersion with (PBAE/GO-/GO+/HP-ß-CD+Brim)6. 
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Figure 39 summarizes the changes in the film composition with the immersion 
time. Each blue circle represents the layers that remained in the film at a determined 
time (t). 
Figure 38 -  Spectra of film after 595h and 763h of immersion and spectra of film before 
immersion with (PBAE/GO-/GO+/HP-ß-CD+Brim)5/ PBAE/GO-/GO+/HP-ß-CD+Brim)3. 
 
57 
 
Figure 39 – Schematic representation of brimonidine release kinetics with the evolution 
of the remaining layers in the film after immersion in the PBS solution.
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4.3 Brimonidine release kinetics of films without PBAE 
 
The results obtained for the brimonidine release from the film without PBAE (see 
figure 22c) were not coherent with a continuous decrease in brimonidine layers. One 
hypothesis to explain this is that the absence of PBAE allows the interdifusion of 
consecutive layers thereby causing a disorder in the brimonidine release.  
Also, after almost 28 days of immersion, the absorption spectrum was coincident 
with that of the film with 11 groups containing HP-ß-CD+Brim. For this reason, the 
desorption study was interrupted and it was concluded the PBAE polymer layer is 
necessary to efficiently release the graphene and brimonidine layers. 
 
4.4 Brimonidine release kinetics conclusion 
 
  
 From these brimonidine release studies, some conclusions can be drawn that 
can be useful to improve films architecture in future works. One refers to the charge of 
the GO surface that seems not to influence the brimonidine release, in terms of total time 
of drug release. However, small differences between the films morphology were detected 
and should be considered if the films architecture is to be improved. Also, the behavior 
of the films during the first three hours of immersion is very different. The film with 
GO+/GO- groups takes about 20 days to release the layers (PBAE/GO+/GO-/HP-ß-
CD+Brim), while the film with GO-/GO+ takes about 10 days to release the same layers. 
These results suggest that the chemical interaction between the negative graphene 
surface and the brimonidine is stronger compared with the positive one, to test these 
interactions it could be performed several tests as use XPS technique, to study the layer 
thickness AFM, ellipsometry and profilometry should be used in the future.  
These results can be interpreted taking into consideration that the chemical 
interaction between the deprotonated carboxylic groups in negative GO and the 
brimonidine secondary amine (-NH) groups should be stronger than the interaction 
between the amine groups of positive GO and the terciary amine groups of brimonidine. 
Despite this difference, the films with the same number of layers show approximately the 
same time of drug release. This result can however be masked by the presence of salts 
in both films and during all the release. Indeed, the salts deposition prevent a more 
accurate analysis of the film and of the PBS solution. Nevertheless, it was evident that 
the presence of GO between the DD layers delay the brimonidine release. Previous 
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results showed that films without GO and with 10 bilayers of (PBAE/Brim) need only few 
minutes to be degraded (53) therefore providing a very fast and undesirable brimonidine 
release.  
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Chapter 5 – Conclusion 
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5. Conclusions  
 
In this thesis, a new drug delivery system that can potentially be used in glaucoma 
treatment was developed and investigated. The system consisted of a multilayer film 
composed of DD layers carrying a drug which is commonly used in ocular diseases – 
brimonidine – encapsulated in 2-hydroxypropyl-ß-cycloextrin and layers of PBAE and 
GO to obtain a delay in drug release. The DD films were fabricated by the LbL technique 
and the growth of films was monitorized by UV-Vis spectroscopy, AFM and HPLC.  
By analyzing the surfaces of PBAE, GO and brimonidine layers by AFM, it was 
concluded that PBAE surface contains grains which may lead to incomplete surface 
coverage and affect the film growth. The phase image of the surface of GO+/GO- showed 
contrast which suggest the presence of salts from the washing solution, this assumption 
is in agreement with the scattering effect observed on the UV-Vis spectra of such films. 
Also, the phase images also suggest that GO layer fully covers the previous PBAE layer, 
revealing that a good interaction is established between the polymer and GO. The 
(PBAE/GO+/GO-/HP-ß-CD+Brim) layer, although showing a low Rrms value, shows an 
incomplete coverage by the brimonidine layer as determined by the phase images, this 
incomplete coverage should be at the origin of spectra overlap occurring for such films. 
The results obtained from UV-Vis analysis also demonstrated a continuous and 
stable films growth for both films architectures, (PBAE/GO+/GO-/HP-ß-CD+Brim) and 
(PBAE/GO-/GO+/HP-ß-CD+Brim). This was also evidenced by the topography and 
phase images obtained from all layers showing relatively homogeneous surfaces. A third 
DD film, without PBAE (PBAE/GO+/GO-/HP-ß-CD+Brim/GO+/GO-/HP-ß-CD+Brim), was 
studied and the results showed a less linear growth, thus indicating that in the absence 
of PBAE interdifusion of consecutive layers should occur and thereby increase disorder 
in the film growth. 
The brimonidine release kinetics was followed by UV-Vis absorption and HPLC 
by immersing the films in a Phosphate Buffer Saline (PBS) solution with properties similar 
to biological fluids, in terms of pH and salts concentration. The polymer PBAE, in the 
presence of a PBS solution, suffers a fast hydrolysis that contributes for a faster 
brimonidine release, but the presence GO between the DD layers delays the brimonidine 
release. 
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The film with the GO+/GO- group layers presented stronger chemical interactions 
between the negative graphene surface and the brimonidine comparing with the film with 
GO-/GO+; this is an important result for the study of time-controlled DD where the order 
of the charged graphene, and also the number of layers, may be adjusted in order to 
delay consecutive amounts of drug. However, the alternated GO layers, in both cases, 
i.e. irrespective to the charge order, are able to delay the brimonidine release, the results 
obtained from the HPLC analysis and their comparison with those obtained from UV-Vis 
analysis allowed to establish a kinetics for the drug release in films where intercalated 
PBAE was used. An important limitation of this study was the occurrence, during the 
drug release analysis, of accumulation of salts on the top of the films. This influenced 
the spectroscopy measurements and prevented the analysis of the drug release kinetics 
over the entire period of time. 
In conclusion, this work contributed to the development of new DD films and some 
important conclusions could be drawn about the how the internal structure of the films 
and composition can influence he films performance when delivering the drug. 
Nevertheless, more experiments are required concerning the corroboration of the 
obtained data, mainly with respect to the desorption studies in order to more precisely 
understand the drug release kinetics.  
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Chapter 6 – Future Work 
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6. Future Work 
 
Although, the results and conclusions obtained in this work allowed to 
comprehend at a certain level the release behavior of brimonidine as well as the structure 
of the prepared films, more accurate studies should be performed to better establish 
those features. In particular, it would be important to monitor in real time the analysis of 
the PBS solutions, i.e. after each immersion on PBS, the solution should be immediately 
analyzed by HPLC, because there is no information on the stability of the solutions 
analyzed.  
Regarding the continuation of this study, in vitro investigations, should be carried 
out to determine the adequate dose to be applied in situ and better evaluate the 
potentiality of these films on the glaucoma treatment. 
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Figure 40 - Steps involved in the synthesis carried out to obtain GO-ß-CD from GO. 
 
Figure 41 - UV-Vis Cecil Aquarius CE7200 spectrophotometer. 
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Figure 42 - Nano-Observer AFM from CSInstruments. 
Figure 43 - Oxygen Plasma Chamber, Gala Instrumente Plasma Prep 2. 
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Figure 44 - HPLC system – Elite LaChrom.   
Figure 45 – 1H-NMR spectrum of dried GO-O in D2O. 
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Table 5 - AFM images of the prepared films with different structures, scan size 2 µm. 
PBAE – Scan size 2 µm 
Topography Phase Profile line 
  
 
PBAE/GO+/GO- – Scan size 2 µm 
Topography Phase Profile line 
   
PBAE/GO+/GO-/HP-ß-CD+Brim – Scan size 2 µm 
Topography Phase Profile line 
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Table 6 - AFM images of the prepared films with different structures, scan size 2 µm. 
PBAE/GO+/GO-/HP-ß-CD+Brim/PBAE – Scan size 2 µm 
Topography Phase Profile line 
 
  
PBAE/GO+/GO-/HP-ß-CD+Brim/PBAE/GO+/GO- – Scan size 2 µm 
Topography Phase Profile line 
   
PBAE/GO+/GO-/HP-ß-CD+Brim/GO+/GO- – Scan size 2 µm 
Topography Phase Profile line 
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Figure 46 - Concentration of brimonidine obtained from HPLC and released to the PBS 
solution from a film composed of eleven groups of (PBAE/GO+/GO-/HP-ß-CD+Brim) as 
a function of the immersion time and obtained. 
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Figure 48 - Spectra of film after 91.25h, 117.25h and 120.25h of immersion and 
spectra of film before immersion with (PBAE/GO-/GO+/HP-ß-CD+Brim)7. 
Figure 47 - Spectra of film after 270h and 393 h of immersion and spectra of film 
before immersion with (PBAE/GO+/GO-/HP-ß-CD+Brim)6. 
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Figure 49 - Chromatogram obtained from the HPLC software, standard concentration 4 
µg/mL of brimonidine. 
 
Figure 50 - Chromatogram obtained from the HPLC software, standard concentration 
10 µg/mL of brimonidine. 
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Figure 51 - Chromatogram obtained from the HPLC software, standard concentration 
15 µg/mL of brimonidine. 
 
 
Figure 52 - Chromatogram obtained from the HPLC software, standard concentration 
20 µg/mL of brimonidine. 
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Figure 53 - Chromatogram obtained from the HPLC software, standard concentration 
24 µg/mL of brimonidine. 
 
